Business Context and Reporting Period
Keros Therapeutics, Inc. (KROS) filed a Current Report on Form 8-K dated December 12, 2021. The Company is an emerging growth company incorporated in Delaware, focused on developing engineered ligand trap compounds. The filing reports the entry into a material definitive agreement on December 12, 2021.
Key Financial Metrics and Transaction Details
This filing does not contain standard financial statements (revenue, profit, cash flow, or debt levels) for the reporting period. Instead, it details a specific licensing transaction with the following financial terms:
- Upfront Payment: $20.0 million to be received from Hansoh (Shanghai) Healthtech Co., Ltd.
- Development Milestones: Up to $26.5 million contingent on specified achievements.
- Sales Milestones: Up to $144.0 million contingent on net sales thresholds.
- Royalties: Tiered percentage ranging from low double digits to high teens on annual net sales.
Material Changes and Agreements
The primary material change is the execution of a License Agreement with Hansoh. Key terms include:
- Scope: Exclusive rights granted to Hansoh to develop, manufacture, and commercialize Keros' proprietary compound KER-050 in mainland China, Hong Kong, and Macau.
- Supply: Hansoh will purchase clinical trial supply and negotiate commercial supply agreements prior to commercialization.
- Exclusivity: Neither party may commercialize competing products in the Territory during the royalty term.
Outlook, Risks, and Contingencies
Management commentary is limited to the announcement of the agreement. The filing outlines specific termination rights and risks:
- Termination: Hansoh may terminate for convenience with notice. Keros may terminate if Hansoh challenges patents or in cases of material breach or bankruptcy.
- Contingencies: Future payments are contingent on regulatory approvals, development milestones, and commercial sales, which are not guaranteed.
- Royalty Term: Payments continue until the latest of 10 years from first sale, patent expiration, or regulatory exclusivity expiration.
Investor Verification Checklist
- Verify the receipt of the $20.0 million upfront payment in subsequent financial filings.
- Review the full text of the License Agreement (to be filed as an exhibit to the 2021 Form 10-K) for detailed milestone definitions.
- Monitor clinical trial progress of KER-050 to assess the likelihood of achieving development milestones.
- Track regulatory approval status of KER-050 in the People's Republic of China, Hong Kong, and Macau.